Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
- PMID: 20679231
- PMCID: PMC2930422
- DOI: 10.1073/pnas.1008522107
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
Abstract
Histone deacetylase inhibitors (HDACi) developed as anti-cancer agents have a high degree of selectivity for killing cancer cells. HDACi induce acetylation of histones and nonhistone proteins, which affect gene expression, cell cycle progression, cell migration, and cell death. The mechanism of the tumor selective action of HDACi is unclear. Here, we show that the HDACi, vorinostat (Suberoylanilide hydroxamic acid, SAHA), induces DNA double-strand breaks (DSBs) in normal (HFS) and cancer (LNCaP, A549) cells. Normal cells in contrast to cancer cells repair the DSBs despite continued culture with vorinostat. In transformed cells, phosphorylated H2AX (gammaH2AX), a marker of DNA DSBs, levels increased with continued culture with vorinostat, whereas in normal cells, this marker decreased with time. Vorinostat induced the accumulation of acetylated histones within 30 min, which could alter chromatin structure-exposing DNA to damage. After a 24-h culture of cells with vorinostat, and reculture without the HDACi, gammaH2AX was undetectable by 2 h in normal cells, while persisting in transformed cells for the duration of culture. Further, we found that vorinostat suppressed DNA DSB repair proteins, e.g., RAD50, MRE11, in cancer but not normal cells. Thus, the HDACi, vorinostat, induces DNA damage which normal but not cancer cells can repair. This DNA damage is associated with cancer cell death. These findings can explain, in part, the selectivity of vorinostat in causing cancer cell death at concentrations that cause little or no normal cell death.
Conflict of interest statement
Conflict of interest statement: Memorial Sloan–Kettering Cancer Center and Columbia University hold patents on suberoylanilide hydroxamic acid (SAHA, vorinostat) and related compounds that were exclusively licensed in 2001 to ATON Pharma, a biotechnology start-up that was wholly acquired by Merck, Inc., in April 2004.
Figures




Similar articles
-
Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors.Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19629-34. doi: 10.1073/pnas.1117544108. Epub 2011 Nov 21. Proc Natl Acad Sci U S A. 2011. PMID: 22106282 Free PMC article.
-
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.Mol Cancer Ther. 2006 Aug;5(8):1967-74. doi: 10.1158/1535-7163.MCT-06-0022. Mol Cancer Ther. 2006. PMID: 16928817
-
Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20003-8. doi: 10.1073/pnas.1013754107. Epub 2010 Oct 29. Proc Natl Acad Sci U S A. 2010. PMID: 21037108 Free PMC article.
-
Immunomodulatory effects of histone deacetylase inhibitors.Curr Mol Med. 2013 May;13(4):640-7. doi: 10.2174/1566524011313040013. Curr Mol Med. 2013. PMID: 23061676 Review.
-
Targeting histone deacetylases: development of vorinostat for the treatment of cancer.Epigenomics. 2010 Jun;2(3):457-65. doi: 10.2217/epi.10.20. Epigenomics. 2010. PMID: 22121904 Review.
Cited by
-
Targeted Therapy for Melanomas Without BRAF V600 Mutation.Curr Oncol Rep. 2022 Dec;24(12):1873-1881. doi: 10.1007/s11912-022-01306-z. Epub 2022 Nov 26. Curr Oncol Rep. 2022. PMID: 36435868 Review.
-
Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site.Molecules. 2016 Oct 15;21(10):1375. doi: 10.3390/molecules21101375. Molecules. 2016. PMID: 27754459 Free PMC article. Review.
-
Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors.Biomaterials. 2015 May;51:208-215. doi: 10.1016/j.biomaterials.2015.02.015. Epub 2015 Feb 19. Biomaterials. 2015. PMID: 25771011 Free PMC article.
-
MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.Oncogene. 2016 Nov 10;35(45):5905-5915. doi: 10.1038/onc.2016.116. Epub 2016 Apr 25. Oncogene. 2016. PMID: 27109101 Free PMC article.
-
The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines.Front Oncol. 2019 Nov 29;9:1301. doi: 10.3389/fonc.2019.01301. eCollection 2019. Front Oncol. 2019. PMID: 31850205 Free PMC article.
References
-
- Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: Current status and overview of recent clinical trials. Drugs. 2009;69:1911–1934. - PubMed
-
- Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov. 2008;7:854–868. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous